Hit enter to search or ESC to close

News

Alterity Therapeutics Presents to Finance News Network

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – June 4, 2019. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is participating in the Finance News Network investor event today in Sydney. The event attracts a large number of retail, high net worth and sophisticated investors. The presentation follows the company’s strong presence at the ...

Alterity Therapeutics commences US investor meetings following positive clinical data

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is today commencing an investor roadshow in the US.  The meetings follow the Company’s presentation of clinical data from its Phase 1 clinical trial program for its investigative drug PBT434 at the American Academy of Neurology Annual Meeting last week. The data indicate that ...

Initial data for Alterity Therapeutics Phase 1 clinical trial released at American Academy of Neurology Annual Meeting

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is today releasing interim clinical data of its Phase 1 clinical trial program for its investigative drug PBT434 at the American Academy of Neurology Annual Meeting in Philadelphia, USA. The Platform Presentation titled: A First in Human Study of PBT434, a Novel Small Molecule Inhibitor ...

Alterity Therapeutics presents at the American Academy of Neurology Annual Meeting

Alterity Therapeutics Limited, (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) will present clinical data from its lead drug candidate PBT434 at the American Academy of Neurology Annual Meeting in Philadelphia, USA, from 5-9th May 2019. Alterity will feature prominently at the Annual Meeting with a Platform Presentation on Sunday 5thMay featuring data from the company’s ...

Receive news from Alterity Therapeutics